Trial Profile
Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Sodium cromoglicate (Primary) ; Sodium cromoglicate
- Indications Systemic mastocytosis
- Focus Therapeutic Use
- Sponsors Patara Pharma
- 27 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 This trial was completed in Germany (End Date: 22 Jul 2016).
- 15 Jun 2016 The trial was completed in Spain.